David Altshuler Sold $965,671 Worth of Vertex Pharmaceuticals (VRTX) Shares; RENNOVA HEALTH (RNVA) Shorts Increased By 2160.78%

David Altshuler, an insider and also EVP – Global Research and CSO of the exchange-traded company Vertex Pharmaceuticals Inc Ma made a big trade, which can’t stay a secret. He unloaded 6,403 shares of the corporation with the deal having an approx. value of $965,671 US Dollars – based on a market stock price of $150.8 a share. It seems he is very active lately as in the last 30 days, he silently unloaded additional 59,842 shares of the company, worth $9,416,445 USD. The probability of this stocks unloading staying undiscovered is quite small due to its volume, with the EVP – Global Research and CSO now having ownership of 69,999 shares — that is 0.03% of the total market capitalization of the Company. The dated 14-02-2018 transaction’s document filed with the U.S. Security and Exchange Commission is available for free here.

RENNOVA HEALTH INCORPORATED (OTCMKTS:RNVA) had an increase of 2160.78% in short interest. RNVA’s SI was 115,300 shares in February as released by FINRA. Its up 2160.78% from 5,100 shares previously. With 1.24 million avg volume, 0 days are for RENNOVA HEALTH INCORPORATED (OTCMKTS:RNVA)’s short sellers to cover RNVA’s short positions. The stock increased 1.17% or $0.0001 during the last trading session, reaching $0.0069. About shares traded. Rennova Health, Inc. (OTCMKTS:RNVA) has declined 96.16% since February 15, 2017 and is downtrending. It has underperformed by 112.86% the S&P500.

Rennova Health, Inc., together with its subsidiaries, provides a suite of healthcare related services and products to healthcare providers in the United States. The company has market cap of $38,913. The firm operates in three divisions: Laboratory Services, Supportive Software Solutions, and Decision Support and Informatics Operations. It currently has negative earnings. It provides toxicology, clinical pharmacogenetics, and esoteric testing services.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It improved, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. State Street accumulated 11.22M shares. Walleye Trading Ltd owns 3,502 shares. Goldman Sachs Gru Incorporated has 0.1% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2.70M shares. Advisory Services Limited Liability has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 181 shares. Art Ltd Liability Com reported 0.27% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 1.37M were accumulated by Renaissance Technologies Limited Com. Intact Invest, Ontario – Canada-based fund reported 1,400 shares. First Citizens Comml Bank & Com holds 2,720 shares. Cibc World Mkts Corp owns 57,531 shares. Prescott Group Incorporated Capital Management Lc owns 0.15% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 5,000 shares. Stonebridge Cap Inc holds 3,947 shares. Opus Point Ptnrs Management Ltd Liability invested 2.49% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Spark Invest Mgmt Limited Liability stated it has 0.64% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Paloma Ptnrs Mngmt Com holds 0.02% or 11,123 shares. Tarbox Family Office holds 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 254 shares.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.83 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 151.21 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Since August 31, 2017, it had 0 insider buys, and 37 insider sales for $109.10 million activity. LEIDEN JEFFREY M had sold 99,563 shares worth $15.63M. $2.56M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit. The insider Chodakewitz Jeffrey sold $270,358. 2,125 shares were sold by SMITH IAN F, worth $330,671. ALTSHULER DAVID had sold 1,796 shares worth $287,360 on Thursday, August 31. Silva Paul M also sold $891,487 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, January 22. Graney Thomas sold $116,511 worth of stock or 777 shares.